Amaç: Nötrofil/lenfosit oranı (NLO) ve monosit/lenfosit oranlarının (MLO), multipl sklerozun (MS) seyri ve progresyonu gibi klinik özelliklerini öngörmede yararlı belirteçler olabilecekleri bildirilmiştir. Dinamik değişiklerle karakterize bu inflamatuar parametrelerin MS'de inflamasyonun en belirgin olduğu ataklı dönemde farklılıklar göstermesi beklenebilir. Bu çalışmada, aynı MS hasta grubunda ataklı ve ataksız dönemlerdeki NLO, MLO ve platelet/lenfosit oranlarının (PLO) araştırılması amaçlanmıştır. Gereç ve Yöntemler: Son 3 yıl içinde akut atak nedeniyle tedavi edilmiş olan MS hastalarının tıbbi kayıtları tarandı. Dâhil edilme kriterlerine uyan 50 hasta çalışmaya alındı. Tüm olgularda iki tam kan sayımı örneğinden (atak sırasında metilprednizolon tedavisinden önce ve ilk tedaviden bir ay sonra alınan) ölçülen NLR, MLR ve PLR düzeyleri laboratuvar ve klinik parametrelere bağlı olarak hesaplandı, kıyaslandı ve değerlendirildi. Bulgular: Ataklı ve ataksız dönemdeki NLO değerleri arasında fark yokken, MLO ve PLO değerleri atak sırasında düşük bulundu (p=0,008, p=0,012). Yedi gün içinde başvuran hastaların MLO ve PLO'ları ataklı dönemde anlamlı düşükken (p=0,048, p=0,023), daha geç başvuranların sadece atak sırasındaki MLO değerleri düşüktü (p=0,037). Sonuç: NLO ve MS hastalarında, atağın ayrımında yararlı bir biyobelirteç olmayabilir. MLO ve PLO değerleri başvuru zamanına göre bazı farklılıklar göstermiştir. MLO ve PLO'nun MS ataklarında yararlı ve dinamik değişiklikler gösteren biyobelirteçler olup, olmadıkları araştırılmaya değer bir konudur.
Anahtar Kelimeler: Multipl skleroz; atak; nötrofil lenfosit oranı; platelet lenfosit oranı; monosit lenfosit oranı
Objective: The neutrophil/lymphocyte ratios (NLR) and monocyte/lymphocyte ratios (MLR) reported as predictive markers for some clinical features of multiple sclerosis (MS). These inflammatory markers might differ during an MS attack where inflammation is expected to be most prominent in the clinical course. We aimed to investigate the NLR, MLR, and platelet/lymphocyte ratios (PLR) during the attack and non-attack periods in MS patients. Material and Methods: The medical records of MS patients that were treated for an acute MS attack in the last 3 years were reviewed. Fifty patients who met the inclusion criteria in the cohort were included into the present study. In all cases, NLR, MLR and PLR from 2 samples of complete blood counts (that were obtained during an attack before methylprednisolone treatment and at least 1 month after the first blood sample) were calculated and compared and also were evaluated according to laboratory and clinical parameters. Results: NLR values were similar in attack and non-attack periods. However, MLR and PLR values were found to be lower during attack (p=0.008, p=0.012, respectively). MLR and PLR were significantly lower during the attack period in the cases who admitted within 7 days (p=0.048, p=0.023, respectively), whereas, only MLR values were lower in the cases who admitted later (p=0.037). Conclusion: NLR does not seem as a useful biomarker for differentiating an MS attack. MLR and PLR values revealed some differences concerning the admission day. It might worth to investigate if MLR and PLR are dynamic and useful biomarkers in MS attacks in further prospective studies.
Keywords: Multiple sclerosis; attack; neutrophil lymphocyte ratio; platelet lymphocyte ratio; monocyte lymphocyte ratio
- Maggi P, Sati P, Nair G, Cortese ICM, Jacobson S, Smith BR, et al. Paramagnetic rim lesions are specific to multiple sclerosis: An international multicenter 3T MRI study. Ann Neurol. 2020;88(5):1034-42. [Crossref] [PubMed]
- Targońska-Stępniak B, Zwolak R, Piotrowski M, Grzechnik K, Majdan M. The relationship between hematological markers of systemic inflammation (neutrophil-to-lymphocyte, plate let-to-lymphocyte, lymphocyte-to-monocyte ratios) and ultrasound disease activity parameters in patients with rheumatoid arthritis. J Clin Med. 2020;9(9):2760. [Crossref] [PubMed] [PMC]
- Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019;19(1):23. [Crossref] [PubMed] [PMC]
- Demirci S, Demirci S, Kutluhan S, Koyuncuoglu HR, Yurekli VA. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int J Neurosci. 2016; 126(8):700-6. [PubMed]
- D'Amico E, Zanghì A, Romano A, Sciandra M, Palumbo GAM, Patti F. The neutrophil-to-lymphocyte ratio is related to disease activity in relapsing remitting multiple sclerosis. Cells. 2019;8(10):1114. [Crossref] [PubMed] [PMC]
- Guzel I, Mungan S, Oztekin ZN, Ak F. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis? J Chin Med Assoc. 2016;79(2):54-7. [Crossref] [PubMed]
- Bisgaard AK, Pihl-Jensen G, Frederiksen JL. The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis. Mult Scler Relat Disord. 2017;18:213-7. [Crossref] [PubMed]
- Hasselbalch IC, Søndergaard HB, Koch-Henriksen N, Olsson A, Ullum H, Sellebjerg F, et al. The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(4):2055217318813183. [Crossref] [PubMed] [PMC]
- Yetkin MF, Mirza M. Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients. J Neuroimmunol. 2020;346:577307. [Crossref] [PubMed]
- Fahmi RM, Ramadan BM, Salah H, Elsaid AF, Shehta N. Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. Mult Scler Relat Disord. 2021;51: 102921. [Crossref] [PubMed]
- Zareifar S, Farahmand Far MR, Golfeshan F, Cohan N. Changes in platelet count and mean platelet volume during infectious and inflammatory disease and their correlation with ESR and CRP. J Clin Lab Anal. 2014;28(3):245-8. [Crossref] [PubMed] [PMC]
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2): 292-302. [Crossref] [PubMed] [PMC]
- Gelibter S, Pisa M, Croese T, Dalla Costa G, Orrico M, Preziosa P, et al. Neutrophil-to-lymphocyte ratio: A marker of neuro-inflammation in multiple sclerosis? J Neurol. 2021; 268(2): 717-23. [Crossref] [PubMed]
- Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, et al. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6): 507-20. [Crossref] [PubMed] [PMC]
- Plantone D, Inglese M, Salvetti M, Koudriavtseva T. A perspective of coagulation dysfunction in multiple sclerosis and in experimental allergic encephalomyelitis. Front Neurol. 2019;9:1175. Erratum in: Front Neurol. 2019; 10:210. [Crossref] [PubMed] [PMC]
.: Process List